CG Oncology, Inc. (CGON) reports a complete response of 75.5% in bladder cancer trials
Recently I’ve put together a list Buy 11 Future Stocks Now. CG Oncology, Inc. stands sixth on the list.
CG Oncology, Inc. (NASDAQ: CGON) is a late-stage clinical biopharmaceutical company that develops bladder-absorbing immunotherapies with a focus on Cretostymogen glenadenorepvec, a targeted lytic viral therapy for bladder cancer. Their lead program targets high-risk BCG non-muscular non-muscular invasive bladder cancer (NMIBC), an area where options other than invasive surgery are limited.
Recent data from the Phase 3 Bond-003 trial published in June 2025 reveals a full response rate of 75.5%, with 42.3% of patients maintaining their response at 24 months. Impressively, 97.3% had no progression to muscle-invasive disease, and 91.6% avoided cystectomy. This treatment is also well tolerated, with no treatment-related adverse events reported in 3rd grade or older.
Cretostimogene stands out as a potential new standard for NMIBC, providing durable cancer control without surgery and maintaining the quality of life of patients. Its promising results have attracted interest in combining it with other treatments such as pembrolizumab, further expanding its treatment potential.
Laboratory medical professionals testing oncology-related products.
CG Oncology, Inc. (NASDAQ:CGON) continues to expand its clinical footprint in a trial that includes both BCG naive and previously treated patients. It is immediately expected that Biology License Applications (BLAs) will be supported by the following powerful Phase 2 combination data: Natural Medicine. The business also offers an extended access program that expands patient reach before full regulatory approval.
Although we acknowledge the potential of GOOGL as an investment, we believe certain AI stocks offer greater potential for a rise and pose a risk of a decline. If you’re looking for a highly undervalued AI stock that can make a significant profit from the tariff and supervision trends of the Trump era, check out our free report. Best Short-Term AI Stocks.
Read next: Best and worst dowstock for the next 12 months and 10 unstoppable stocks that can double your money.
Disclosure: None.